SOLICITATION NOTICE
R -- Title: ?A Cost-Effectiveness Model of Disease-Modifying Therapies ForThe Treatment of Multiple Sclerosis (MS)?
- Notice Date
- 8/17/2004
- Notice Type
- Solicitation Notice
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, Program Support Center, Division of Acquisition Management, Parklawn Building Room 5-101 5600 Fishers Lane, Rockville, MD, 20857
- ZIP Code
- 20857
- Solicitation Number
- Reference-Number-04R000207
- Response Due
- 8/27/2004
- Archive Date
- 9/11/2004
- Point of Contact
- Julia Savoy, Contract Specialist, Phone 301-443-1386, Fax 301-443-3849, - Julia Savoy, Contract Specialist, Phone 301-443-1386, Fax 301-443-3849,
- E-Mail Address
-
jsavoy@psc.gov, jsavoy@psc.gov
- Description
- The U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality through the Program Support Center, plans to award a 9-month sole source simplified acquisition to School of Health and Related Research (ScHARR) University of Sheffield, Principle Investigator, Chris McCabe, Ph.d., 85 Wilkinson Street, Sheffield, S102GJ. Dr. McCabe was the principal investigator of a cost-effectiveness analysis of the four disease-modifying therapies for Multiple Sclerosis (MS) funded by National Institute of Clinical Excellence ( NICE). NICE works on behalf of the UK?s National Health Service to make recommendations on treatment and care using the best available evidence. The contractor shall have no conflicts of interest that might influence the outcome of the cost-effectiveness study. To the best of the knowledge of CMS, no other cost-effectiveness model exists for the treatment of MS that was built on long-term natural history of the disease, incorporates the results of a recent systematic review, utilized state-of-the-art probabilistic sensitivity analyses, incorporates robust utility measures and was not funded by industry. The purpose of this requirement is to provide a cost-effectiveness model of disease-modifying therapies for the treatment of MS. The final report provided under this requirement will be used to inform the evaluation of the demonstration project that will pay for self-administered drugs and biologicals prescribed as replacements for drugs currently covered under Medicare Part B. The contractor shall work with AHRQ staff to ensure that the cost-effectiveness methods used are consistent with standards set by the US Panel on Cost-effectiveness in Health and Medicine. The contractor shall use state-of-the art stochastic methods to model the underlying uncertainty of the cost-effectiveness measures. The contractor should keep in mind that this study will help set the standards for the conduct of future cost-effectiveness analyses within CMS. THE PROPOSED SIMPLIFIED ACQUISITION ACTION IS FOR SUPPLIES AND SERVICES FOR WHICH THE GOVERNMENT INTENDS TO SOLICIT AND NEGOTIATE WITH ONLY ONE SOURCE UNDER AUTHORITY OF FAR 6.302. INTERESTED PERSONS MAY IDENTIFY THEIR INTEREST AND CAPABILITY TO RESPOND TO THE REQUIREMENT OR SUBMIT PROPOSALS WITHIN 10 DAYS AFTER THE DATE OF PUBLICATION OF THE NOTICE. A DETERMINATION BY THE GOVERNMENT NOT TO COMPETE THIS PROPOSED SIMPLIFIED ACQUISITIONS BASED UPON RESPONSES TO THIS NOTICE IS SOLELY WITHIN THE DISCRETION OF THE GOVERNMENT. INFORMATION RECEIVED WILL NORMALLY BE CONSIDERED SOLELY FOR THE PURPOSE OF DETERMINING WHETHER TO CONDUCT A COMPETITIVE PROCUREMENT. NO SOLICITATION IS AVAILABLE.
- Record
- SN00645225-W 20040819/040817211851 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |